PT  - JOURNAL ARTICLE
AU  - Sabrina Della Patrona
AU  - Andrea Zanini
AU  - Marina Aiello
AU  - Daniela Adamo
AU  - Silvia Casale
AU  - Francesca Cherubino
AU  - Eleonora Raimondi
AU  - Elisabetta Zampogna
AU  - Alfredo Chetta
AU  - Antonio Spanevello
TI  - Estimation of minimum clinically important difference in EQ-VAS score after pulmonary rehabilitation in COPD patients
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P3669
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P3669.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P3669.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - Introduction: The effect of pulmonary rehabilitation (PR) on EuroQol (EQ-5D) in COPD has been poorly investigated.In addition,conflicting results have been so far reported about the VAS (Visual Analogic Scale) component of EQ-5D (EQ-VAS).Aim: To evaluate the responsiveness of EQ-VAS to PR and its relationship with clinical and functional parametersin COPD patients.To define minimum clinically important difference (MCID) estimate for the EQ-VAS after PR.Methods:468 stable moderate-to-severe COPD inpatients,allocated to a three-weeks PR program, were retrospectively evaluated.EQ-VAS was assessed before and after PR and its relationship with baseline pulmonary function and with changes in 6MWT and dyspnea (BDI/TDI) after PRwere evaluated.Using an anchor-based approach and receiver operating characteristic (ROC)curves,the EQ-VAS change cutoff that identified patients achieving the known MCID for TDI with PR was identified.Results: 439 patients (94%, mean FEV1 55.3% predicted) were able to complete pre- and post-PR VAS score. After PR, EQ-VAS increased from 58±17 to 72±15 (ΔEQ-VAS 14±12, p<0.001). ΔEQ-VAS was negatively related to baseline FEV1 (r=-032, p<0.001) and positively to TDI (r=0.50, p<0.001) and 6MWD (r=0.46, p<0.001) changes. ROC curves identified an EQ-VAS change cutoff of 8 points, as the best discriminating value to identify the MCID for TDI (area under curve: 0.845,p<0.001).Conclusions: Our study shows that in stable moderate-to-severe COPD inpatients, EQ-VAS is a valid and reliable tool to assess theresponsiveness to PR, with an estimated MCIDof 8 points. The EQ-VAS can be a practical alternative to more time-consuming measures of HrQoL.